EcoDrugPlus

Udp-Glucose Ceramide Glucosyltransferase

Ensembl ID : ENSOMYG00000006360
Gene Symbol: UGCG
2 Cross references
204 Possible Orthologues:

Wee1 G2 Checkpoint Kinase

Ensembl ID : ENSOMYG00000038097
Gene Symbol: WEE1
1 Cross references
199 Possible Orthologues:

Wee1 G2 Checkpoint Kinase

Ensembl ID : ENSOMYG00000041460
Gene Symbol: WEE1
1 Cross references
142 Possible Orthologues:

Wee1 G2 Checkpoint Kinase

Ensembl ID : ENSOMYG00000033416
Gene Symbol: WEE1
1 Cross references
199 Possible Orthologues:

Wee1 G2 Checkpoint Kinase

Ensembl ID : ENSOMYG00000034214
Gene Symbol: WEE1
1 Cross references
142 Possible Orthologues:

Yes Proto-Oncogene 1, Src Family Tyrosine Kinase

Ensembl ID : ENSOMYG00000017136
Gene Symbol: YES1
1 Cross references
202 Possible Orthologues:

Acetylcholinesterase

Ensembl ID : ENSOMYG00000041707
Gene Symbol: ACHE
1 Cross references
227 Possible Orthologues:

Activin A Receptor Type 2ba

Ensembl ID : ENSOMYG00000013080
Gene Symbol: ACVR2BA
1 Cross references
187 Possible Orthologues:

Activin Receptor Iib

Ensembl ID : ENSOMYG00000032825
Gene Symbol: ACTRIIB
2 Cross references
187 Possible Orthologues:

Adenosine A2a Receptor A

Ensembl ID : ENSOMYG00000012575
Gene Symbol: ADORA2AA
1 Cross references
184 Possible Orthologues:

Adenosine A2a Receptor A

Ensembl ID : ENSOMYG00000041298
Gene Symbol: ADORA2AA
2 Cross references
184 Possible Orthologues:

Adenosine A2b Receptor

Ensembl ID : ENSOMYG00000015627
Gene Symbol: ADORA2B
1 Cross references
191 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).